Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Chemed Corp Market Cap
From what 4 stock analysts predict, the share price for Chemed Corp (CHE) might increase by 17.04% in the next year. This is based on a 12-month average estimation for CHE. Price targets go from $650 to $708. The majority of stock analysts believe CHE is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
CHE is a stock in Healthcare which has been forecasted to be worth $685 as an average. On the higher end, the forecast price is $708 USD by from and on the lower end CHE is forecasted to be $650 by Michael Wiederhorn from Oppenheimer.
These are the latest 20 analyst ratings of CHE.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Ben Hendrix RBC Capital | Outperform | $697 | Maintains | May 21, 2024 |
| Ben Hendrix RBC Capital | Outperform | $712 | Maintains | Mar 4, 2024 |
| Michael Wiederhorn Oppenheimer | Outperform | $650 | Maintains | Feb 29, 2024 |
| Michael Wiederhorn Oppenheimer | Outperform | $625 | Maintains | Jan 17, 2024 |
| Ben Hendrix RBC Capital | Outperform | $604 | Maintains | Oct 30, 2023 |
| Ben Hendrix RBC Capital | Outperform | $576 | Maintains | Jul 31, 2023 |
| Michael Wiederhorn Oppenheimer | Outperform | $590 | Maintains | Jul 27, 2023 |
| Ben Hendrix RBC Capital | Outperform | $610 | Maintains | May 1, 2023 |
| Michael Wiederhorn Oppenheimer | Outperform | $610 | Maintains | Apr 28, 2023 |
| Ben Hendrix RBC Capital | Outperform | $587 | Maintains | Feb 27, 2023 |
| Ben Hendrix RBC Capital | Outperform | $545 | Maintains | Nov 3, 2022 |
| Ben Hendrix RBC Capital | Outperform | $541 | Maintains | Aug 1, 2022 |
| Ben Hendrix RBC Capital | Outperform | $592 | Maintains | Apr 28, 2022 |
| Frank Morgan RBC Capital | Outperform | $579 | Maintains | Mar 4, 2022 |
| Frank Morgan RBC Capital | Outperform | $609 | Maintains | Jul 29, 2021 |
| Michael Wiederhorn Oppenheimer | Outperform | $580 | Maintains | Feb 25, 2021 |
| Frank Morgan RBC Capital | Outperform | $535 | Upgrade | Mar 11, 2020 |
Oppenheimer | Outperform | $535 | Maintains | Feb 19, 2020 |
Oppenheimer | Perform | $470 | Maintains | Nov 25, 2019 |
JMP Securities | Market Outperform | Upgrade | Nov 1, 2019 |
When did it IPO
1973
Staff Count
15,087
Country
United States
Sector/Industry
Healthcare/Medical Care Facilities
CEO
Mr. Kevin J. McNamara
Market Cap
$8.89B
In 2023, CHE generated $2.26B in revenue, which was a increase of 6.06% from the previous year. This can be seen as a signal that CHE's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 01 Oct 2024
Sentiment - NEUTRAL
Source - CNBC Television
Summary - The Investment Committee has released a list of top stocks to watch for the second half of the year.
Why It Matters - The Investment Committee's top stock picks signal potential growth opportunities and strategic insights, guiding investor decisions for the upcoming period.
Mon, 30 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Investors are evaluating Amedisys (AMED) and Chemed (CHE) for potential value opportunities in the Medical - Outpatient and Home Healthcare sector.
Why It Matters - The comparison of Amedisys and Chemed highlights potential investment opportunities in the outpatient and home healthcare sector, influencing stock selection and portfolio strategy.
Wed, 25 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - LEO Pharma announced its largest EADV program, featuring 5 late-breaking abstracts and 23 posters presenting clinical and real-world data.
Why It Matters - LEO Pharma's extensive EADV program signals strong clinical advancements, potentially boosting investor confidence in its growth prospects and market position.
Wed, 18 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks Style Scores provide a tool for investors to identify top-rated stocks that align with their investing style, enhancing stock selection strategies.
Why It Matters - Zacks Style Scores provide a streamlined method for identifying high-potential stocks, enhancing investment strategies and potentially improving returns.
Fri, 13 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Chemed Corporation (NYSE: CHE) will release Q3 2024 financial results on October 29, 2024, and host a conference call on October 30, 2024, at 10 a.m. ET for discussion.
Why It Matters - Chemed's upcoming financial results and conference call will provide insights into its performance and future outlook, influencing stock valuation and investment decisions.
Fri, 23 Aug 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Chemed (CHE) reported earnings 30 days ago; investors should monitor upcoming developments and market reactions for future stock performance.
Why It Matters - Chemed's recent earnings report can influence investor sentiment and stock performance. Future guidance or market reactions can indicate growth potential or risks, impacting investment decisions.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
